Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
0 hedge funds and large institutions have $0 invested in Ambrx Biopharma Inc in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.
100% less funds holding
Funds holding: 68 → 0 (-68)
100% less funds holding in top 10
Funds holding in top 10: 6 → 0 (-6)
100% less capital invested
Capital invested by funds: $913M → $0 (-$913M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 68
101.49% less ownership
Funds ownership: 101.49% → 0% (-101%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$238M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$160M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$62M |
| 4 |
D.E. Shaw & Co
New York
|
-$60.4M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$52.8M |
AMAM Hedge Fund Activity: Q1 2024 in Review
0 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2024, worth a combined $0 — down 100% from $913M a quarter earlier.
Sellers outnumbered buyers: 68 funds closed out of AMAM and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Darwin Global Management, exiting entirely with an estimated $238M sold.
- 0 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2024, down from 68 in Q4 2023.
- Funds reported $0 of Ambrx Biopharma Inc stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Ambrx Biopharma Inc positions in Q1 2024 and 68 closed out, a net change of -68 holders.
- The largest Ambrx Biopharma Inc seller in Q1 2024 was Darwin Global Management, an estimated $238M sold.
Based on aggregated 13F filings for Q1 2024.